Axogen, Inc. Common Stock vs. Neuraxis, Inc.
Axogen, Inc. Common Stock (AXGN) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| AXGN | NRXS | |
|---|---|---|
| Market Cap | $2.27 billion | $87.15 million |
| Revenue (TTM) | $251.17 million | $5.32 million |
| Net Income (TTM) | $-33,548,000 | $-7,678,631 |
AXGN leads on 2 of 3 size & scale factors.
Valuation
| AXGN | NRXS | |
|---|---|---|
| Price / Book | 8.84 | 12.94 |
| Price / Sales | 9.02 | 16.39 |
AXGN leads on 2 of 2 valuation factors.
Profitability
| AXGN | NRXS | |
|---|---|---|
| Net Margin | -13.36% | -144.44% |
| Return on Equity | -13.09% | -114.01% |
AXGN leads on 2 of 2 profitability factors.
Risk & Sentiment
| AXGN | NRXS | |
|---|---|---|
| Short Interest | 2.05% | 0.02% |
NRXS leads on 1 of 1 risk & sentiment factors.
Dig deeper: AXGN overview, AXGN financials, NRXS overview, NRXS financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.